AI-Powered HeartFlow ONE Shows 7-Year Success in Long-Term Risk Assessment for Coronary Artery Disease

HeartFlow, Inc., the leading provider of AI-powered heart care solutions, announced groundbreaking seven-year data validating the effectiveness of its HeartFlow ONE platform in assessing long-term risks for coronary artery disease (CAD).

Long-Term Risk Prediction with FFR_CT Analysis

Presented at the 36th annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C., the ADVANCE-DK data demonstrates that the HeartFlow platform, which incorporates AI-enabled fractional flow reserve computed tomography (FFR_CT) and Plaque Analysis, significantly improves clinicians’ ability to predict and mitigate adverse cardiovascular events in clinically stable, symptomatic patients.

Identifying High-Risk Patients

The study, a subset of the larger ADVANCE Registry, focused on three patient groups: those with normal FFR_CT, those who underwent complete revascularization (CR), and those with incomplete revascularization (IR). The findings showed that patients with IR, as assessed by FFR_CT, faced a significantly higher long-term risk of adverse events compared to patients with CR or normal FFR_CT assessments.

• Patients with IR had a 16.2% risk of adverse events, compared to 7.8% for CR and 5.7% for normal FFR_CT.
• The combination of plaque quantification, characterization, and lesion-specific physiology from FFR_CT proved superior to traditional CCTA in predicting adverse cardiovascular events.

The Importance of FFR_CT and Plaque Analysis

“The ADVANCE-DK data underscores the power of HeartFlow technologies to move beyond immediate CAD risks and provide insights into long-term residual risks across the disease spectrum,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer of HeartFlow. “By combining lesion-specific FFR_CT with plaque analysis, clinicians gain a more comprehensive understanding of each patient’s individual risks and can make more informed treatment decisions.”

Fighting Heart Disease with AI-Powered Solutions

HeartFlow is committed to making cutting-edge heart care accessible to more patients worldwide. With over 1,300 institutions using its innovative solutions, the company continues to generate strong clinical evidence supporting the effectiveness of its AI-powered platform in improving diagnosis and management of coronary artery disease.

Learn More About HeartFlow ONE

Ready to explore how HeartFlow ONE can revolutionize your CAD care? Visit our website to learn more about our AI-powered solutions.